Healthesystems is exhibiting at the PA Workers’ Comp Conference, an educational seminar for professionals within the field of PA workers’ comp.
Healthesystems is attending the National Council of Self-Insurers’ conference, which brings together professionals from companies who self-insure their workers’ compensation.
Approval Date: Jul 2023
Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA
Approval Date: Jun 2023
For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema
Approval Date: Jun 2023
For the treatment of hypertension and coronary artery disease
Approval Date: Jun 2023
Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.
Approval Date: May 2023
Indicated for the management of selected, refractory, patients with epilepsy, on stable regimens of anti-epileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity
Approval Date: May 2023
Indicated for the control of absence (petit mal) seizures that are refractory to other drugs
Approval Date: May 2023
A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis
Approval Date: May 2023
Indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19
Approval Date: May 2023
Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes
Approval Date: May 2023
Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use
